Ravi Passi, MD
Internal Medicine · Rockville, MDNPI 1114921665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$602
- Novo Nordisk$382
- Boehringer Ingelheim$376
- Amgen$369
- Lilly USA, LLC$321
- Novartis$309
- plus $3K from 39 others
Across 293 payments — averaging $5558.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$657K
- Pfizer$554K
- Genentech, Inc.$201K
- Currax Pharmaceuticals LLC$122K
- Exact Sciences$39K
- AstraZeneca$35K
- plus $21K from 2 others
What the payments were for
- Speaking & faculty fees$451%
- Food & beverage$4,90298%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,027 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 282 | $147,422 |
| JardianceEmpagliflozin | 112 | $105,759 |
| JanuviaSitagliptin Phosphate | 80 | $65,447 |
| OzempicSemaglutide | 31 | $60,470 |
| XareltoRivaroxaban | 99 | $55,998 |
| TrulicityDulaglutide | 45 | $36,752 |
| Invega SustennaPaliperidone Palmitate | 13 | $32,199 |
| TivicayDolutegravir Sodium | 13 | $30,964 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $27,891 |
| MyrbetriqMirabegron | 47 | $23,680 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $22,295 |
| EntrestoSacubitril/Valsartan | 42 | $18,003 |
| TradjentaLinagliptin | 31 | $15,797 |
| FarxigaDapagliflozin Propanediol | 15 | $14,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $14,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $147,422282 claims |
| Boehringer IngelheimJardiance, Tradjenta | $376 | $121,556143 claims |
| Johnson & JohnsonXarelto, Invega Sustenna, Procrit | $89 | $101,743145 claims |
| MerckJanuvia, Janumet | $55 | $87,743104 claims |
| Novo NordiskOzempic | $382 | $60,47031 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $321 | $43,816170 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $108 | $32,86667 claims |
| GileadDescovy | $36 | $27,89112 claims |
| NovartisEntresto, Exelon | $309 | $27,66354 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $23,68047 claims |
| AstraZenecaFarxiga, Lokelma | $256 | $21,15933 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $6,95329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Rockville
- Scott KoenigRockville$20K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.